• OUTLOOK ARENA
  • VIEWS ON NEWS
  • OCTOBER 17, 2000

Dr.Reddy’s: Outperforms industry again

Dr. Reddy’s Laboratories (DRL) announced a 46% growth in the turnover for the second quarter of the current year. (This does not include the numbers for Cheminor Drugs, which is slated to be merged with the company in the current year. The merger ratio has been fixed at 9 shares of Dr. Reddy’s for every 25 shares of Cheminor.) The full results are slated to be announced on October 30th 2000.

Of the total turnover of Rs 1,135.7 m, 68% is accounted by finished dosages, 30% by bulk actives and the balance by diagnostics. The first half turnover amounts to Rs 3,039.69 m, which implies a growth of 25%. This is nearly double the industry growth of around 13% in the current year.

We project a turnover of Rs 8,658 m in the current year (which includes the numbers of Cheminor and American Remedies) and an EPS in the range of Rs 35 for the full year FY2001. The current price of Rs 1,380 implies an earning multiple of 39.4 times on the full year earnings. There seems to be no dramatic undervlaution at this stage unless the company were to announce a major R & D breakthrough.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407